Zoetis' plan to buy Neogen's animal genomics business for $160 million has hit a snag. Australia's competition regulator, the ACCC, has decided the deal needs a deeper look—a Phase 2 assessment—because it might substantially lessen competition in the market for genomic testing of dairy cattle, beef cattle, and sheep.

Both Zoetis (ZTS) and Neogen (NEOG) are big players in this niche but important field. Genomic testing helps farmers make better breeding decisions, improve herd health, and boost productivity. If Zoetis absorbs Neogen's genomics division, it would effectively corner a massive share of that market in Australia.

But the ACCC isn't just worried about market concentration in testing services. It's also looking at something more subtle: data. The regulator is evaluating the competitive impact of Zoetis gaining exclusive access to a vastly increased breadth and volume of genetic data on Australian sheep and cattle. In an era where data is king, owning the genetic blueprint of a country's livestock could give a company a powerful, long-term advantage that competitors can't easily replicate.

Zoetis, a global animal health leader, first announced the deal in March. The cash transaction is designed to bolster its Precision Animal Health portfolio, which focuses on using data and technology to deliver predictive insights and individualized care for animals. The company's leadership has emphasized that integrating Neogen's genomics capabilities—including its advanced software, genotyping platforms, and five labs spread across the U.S., U.K., China, Australia, and Brazil—will fuel future innovation in livestock health.

Neogen's genomics business is no small operation. It serves customers in more than 120 countries and is recognized as a leader in U.S. dairy and beef genomics. Its technology includes both sequencing and fixed-array genotyping, along with sophisticated data solutions.

For now, the deal is in regulatory limbo. The ACCC's Phase 2 review means a more thorough investigation, with a final decision likely months away. Zoetis shares were up 1.47% at $77.15 on Friday, suggesting investors aren't panicking—yet. But the outcome of this review could shape not just this transaction, but also how regulators around the world think about data ownership in agribusiness.

Photo by JHVEPhoto via Shutterstock